Donald L. Zuhn, Jr. is a partner with McDonnell Boehnen Hulbert & Berghoff LLP and serves as co-Chair of the firm’s Biotechnology & Pharmaceuticals Practice Group. Dr. Zuhn has more than a decade of experience in all aspects of patent prosecution, litigation, counseling, and licensing. He represents a variety of clients, including biotechnology and pharmaceutical companies both large and small, and universities.
Dr. Zuhn joined MBHB in 1998. He maintained a full-time position as a law clerk while attending law school at night until his graduation in 2002.
- IAM Patent 1000
- IAM Strategy 300 — The World’s Leading IP Strategists
- IAM Global Leaders Guide
- Best Lawyers in America (2015-2024)
- JD Supra Readers’ Choice Awards
- Managing IP Stars
- LMG Life Sciences Stars
Founding author and editor of the Patent Docs weblog, a site focusing on biotechnology and pharmaceutical patent law.
Contributor to Patently-O, a patent law weblog.
Donald L. Zuhn, Jr. and Paul H. Berghoff, “The Evolution of the Written Description Requirement in the Context of Biotechnological Inventions”, Midwestern Biotech Intellectual Property Law Symposium, June 2004.
Kevin E. Noonan, Michael S. Greenfield, and Donald L. Zuhn, “Paradise Lost: The Uncertain Future of Research Tool Patents”, Intellectual Property & Technology Law Journal, March 2003.
“DNA Patentability: Shutting the Door to the Utility Requirement”, The John Marshall Law Review, Summer 2001.
